Đang chuẩn bị liên kết để tải về tài liệu:
Effect-site concentration of propofol required for LMA-Supreme™ insertion with and without remifentanil: A randomized controlled trial

A new supraglottic device, the LMA-Supreme™, has recently become available for clinical use. Information on anaesthetic and co-adjuvant requirements for insertion of the LMA-Supreme™ is limited. The present study aimed to evaluate the optimal effect-site concentration of propofol in 50 % (EC50) of adults necessary for successful insertion of the LMA-Supreme™ and to examine remifentanil’s effect on propofol requirements. |